Guardant Health, Inc.

Guardant Health, Inc. is a precision oncology company focused on cancer care. The company transforms patient care by providing insights into disease drivers through advanced blood and tissue tests, real-world data, and AI analytics. Their tests aim to improve outcomes across all stages of care, including early cancer screening, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For advanced-stage cancer patients, Guardant Health offers the Guardant360 Liquid test (formerly Guardant360 LDT) and the Guardant360 CDx test. The Guardant360 CDx test is the first comprehensive liquid biopsy test approved by the U.S. Food and Drug Administration (FDA) for tumor mutation profiling with solid tumors and as a companion diagnostic for non-small cell lung cancer (NSCLC), colorectal cancer, and breast cancer. They also provide the Guardant360 Tissue test for advanced-stage cancer and the Guardant Reveal test for detecting residual and recurring disease in early-stage colorectal, breast, and lung cancer patients. The Guardant Reveal test has been expanded to include late-stage therapy response monitoring for patients with solid tumors. The product portfolio is powered by the Smart Platform, which uses methylation technology with genomic, epigenomic, and RNA-based data, proprietary chemistry, advanced algorithms, and the InfinityAI learning engine. Guardant Health collaborates with biopharmaceutical companies in clinical studies, offering the aforementioned tests, as well as the GuardantINFINITY blood test (also powered by the Smart Platform) and the GuardantOMNI blood test for advanced-stage cancer. The GuardantINFORM platform, developed using data from their tests and AI-enabled analytical tools, assists biopharmaceutical companies in accelerating precision oncology drug development by providing insights into tumor evolution and treatment resistance across various biomarker-driven cancers.